antibody-drug conjugates

News

Image of a pair of lungs on an orange-beige background

Pfizer's Seagen-derived ADC pipeline suffers a setback

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

Ipsen licenses Simcere ADC in $1bn-plus deal

Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.

News

Daiichi Sankyo launches its STING operation against cancer

Daiichi Sankyo has started clinical testing of a STING agonist for cancer, a class that has been hit by safety issues and discontinued programmes.

News

As Blenrep returns, GSK adds another ADC to cancer pipeline

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.

News

Dr Dominik Schumacher, Tubulis' co-founder and chief executive

Germany's Tubulis raises €308m for ADC pipeline

Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.

News

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.

Pfizer's Seagen-derived ADC pipeline suffers a setback

Ipsen licenses Simcere ADC in $1bn-plus deal

Daiichi Sankyo launches its STING operation against cancer

As Blenrep returns, GSK adds another ADC to cancer pipeline

Germany's Tubulis raises €308m for ADC pipeline

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

antibody-drug conjugates

Editor's Picks